NCT03483103 2023-12-20Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)Juno Therapeutics, a Subsidiary of CelgenePhase 2 Completed74 enrolled 43 charts 1 FDA